SAMHSA extends methadone take-home flexibilities initiated during pandemic
The Substance Abuse and Mental Health Services Administration yesterday extended certain methadone take-home flexibilities for opioid treatment programs until one year after the end of the COVID-19 public health emergency, and said it is considering ways to make the flexibilities permanent.
SAMHSA in 2020 allowed states to request a blanket exception to allow stable patients in an opioid treatment program to receive 28 days of take-home doses of their OUD medication, and other eligible patients to receive up to 14 days of take-home medication, which the agency said has enhanced and encouraged use of treatment services.
Related News Articles
Headline
SAMHSA finds declines in use of alcohol, drugs in latest annual survey on drug use and mental health
The Substance Abuse and Mental Health Services Administration July 27 released results from its latest national survey on drug use and mental health. The…
Headline
The AHA’s Bridge to Care initiative highlights how hospitals and health systems are strengthening care transitions and supporting ongoing treatment engagement…
Headline
In this conversation, a team from the University Medical Center New Orleans — LSU School of Medicine’s Benjamin Springgate, M.D., professor of …
Headline
Heidi Bray, DNP, nurse practitioner and hospitalist at Providence St. Peter Hospital, explores how hospitals can improve opioid use disorder treatment through…
Headline
The AHA will host a webinar June 16 at 1 p.m. ET that will share insights from its Bridge to Care Toolkit, designed to help hospitals and health systems…
Headline
The Drug Enforcement Administration today released a final rule implementing provisions from the Restoring Hope for Mental Health and Well-Being Act of 2022,…